<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436917</url>
  </required_header>
  <id_info>
    <org_study_id>MC05C8</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC05C8</secondary_id>
    <secondary_id>2330-05</secondary_id>
    <nct_id>NCT00436917</nct_id>
  </id_info>
  <brief_title>Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer</brief_title>
  <official_title>Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast
      cancer.

      PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or
      osteoporosis in postmenopausal women receiving letrozole for stage I, stage II, or stage IIIA
      primary breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess changes in total lumbar spine bone mineral density (BMD) from baseline to 12
           months in postmenopausal women treated with zoledronate for osteopenia or osteoporosis
           and letrozole for hormone receptor-positive, stage I-IIIA primary breast cancer.

      Secondary

        -  Determine changes in total lumbar spine BMD from baseline to 2, 3, 4, and 5 years in
           these patients.

        -  Determine changes in femoral neck BMD from baseline to 1, 2, 3, 4, and 5 years in these
           patients.

        -  Determine time to disease progression in these patients.

      OUTLINE: This is an open-label, multicenter study.

        -  Adjuvant aromatase inhibitor therapy: Patients receive oral letrozole daily for up to 5
           years in the absence of disease progression or unacceptable toxicity.

        -  Osteoporosis management: Patients receive zoledronate IV over 15 minutes on day 1.
           Patients also receive oral elemental calcium twice daily and oral vitamin D daily for 6
           months. Treatment repeats every 6 months for up to 5 years in the absence of disease
           progression or unacceptable toxicity.

      Patients undergo total lumbar spine and hip (femoral neck) bone density testing by dual
      energy x-ray absorptiometry (DXA) at baseline and annually for 5 years.

      After completion of study therapy, patients are followed at 4 weeks.

      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">May 9, 2016</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Lumbar Spine BMD as Measured by DXA at Baseline and at 24, 36, 48, and 60 &gt; Months</measure>
    <time_frame>5 yr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck BMD as Measured by DXA at Baseline and at 12, 24, 36, 48, and 60 Months</measure>
    <time_frame>5 yr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Toxicity as Assessed by NCI CTCAE v3.0</measure>
    <time_frame>5 yr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>5 yr</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>zoledronic acid</description>
    <arm_group_label>zoledronic acid</arm_group_label>
    <other_name>Zometa®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Letrozole as adjuvant therapy</intervention_name>
    <description>standard care</description>
    <arm_group_label>zoledronic acid</arm_group_label>
    <other_name>Femara®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of localized breast cancer

               -  Stage I-IIIA disease

               -  Adequately treated breast cancer

                    -  No clinical or radiological evidence of recurrent or metastatic disease

          -  Baseline total lumbar spine or femoral neck bone mineral density T-score &lt; -2.0
             standard deviation (e.g., a patient with a T score of -2.1 is eligible)

          -  Hormone-receptor status:

               -  Estrogen receptor and/or progesterone receptor-positive breast cancer

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal, defined by 1 of the following criteria:

               -  Age &gt; 55 years with cessation of menses

               -  Age ≤ 55 years with spontaneous cessation of menses for &gt; 1 year

               -  Age ≤ 55 years with spontaneous cessation of menses for ≤ 1 year, but amenorrheic
                  (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal
                  estradiol levels

               -  Bilateral oophorectomy

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 5 years

          -  WBC ≥ 3,000/mm³ OR granulocyte count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN

          -  Creatinine &lt; 2.0 mg/dL

          -  Creatinine clearance ≥ 45 mL/min

          -  No hypercalcemia (i.e., calcium level &gt; 1 mg/dL above ULN) OR hypocalcemia (i.e.,
             calcium level &gt; 0.5 mg/dL below lower limit of normal) within the past 6 months

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  No other nonmalignant systemic diseases, including any of the following:

               -  Uncontrolled infection

               -  Uncontrolled diabetes mellitus

               -  Uncontrolled thyroid dysfunction

               -  Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's
                  disease, osteogenesis imperfecta)

               -  Malabsorption syndrome

          -  No uncontrolled seizure disorders associated with falls

          -  No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium,
             or vitamin D

          -  No concurrent active dental problems, including any of the following:

               -  Infection of the teeth or jawbone (maxillary or mandibular)

               -  Dental or fixture trauma

               -  Prior or current diagnosis of osteonecrosis of the jaw

               -  Exposed bone in the mouth

               -  Slow healing after dental procedures

          -  No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any
             of the following:

               -  History of surgery at the lumbosacral spine, with or without implantable devices

               -  Scoliosis with a Cobb angle &gt; 15 degrees at the lumbar spine

               -  Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence
                  of sclerotic abdominal aorta sufficient to interfere with DXA scan

               -  Disease of the spine that would preclude the proper acquisition of a lumbar spine
                  DXA

          -  No condition that would preclude study follow-up or compliance

          -  No psychiatric illness that would preclude giving informed consent

        PRIOR CONCURRENT THERAPY:

          -  More than 3 weeks since prior and no other concurrent oral bisphosphonates

          -  No prior intravenous bisphosphonates

          -  No prior aromatase inhibitor therapy

          -  More than 6 months since prior anabolic steroids or growth hormone

          -  More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone
             resorption (e.g., calcitonin, mithramycin, or gallium nitrate)

          -  More than 30 days since prior systemic investigational drug and/or device

          -  More than 7 days since prior topical investigational drug

          -  More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g.,
             extraction, implants)

          -  Concurrent short-term corticosteroid therapy allowed

          -  No concurrent sodium fluoride, parathyroid hormone, or tibolone

          -  No other concurrent investigational drug or device
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Hines, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles L. Loprinzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast. 2010 Apr;19(2):92-6. doi: 10.1016/j.breast.2009.12.001. Epub 2010 Jan 15.</citation>
    <PMID>20079640</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <results_first_submitted>July 19, 2011</results_first_submitted>
  <results_first_submitted_qc>July 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2011</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty participants were recruited between June 2006 and July 2007 at 6 individual sites participating in the Mayo Clinic Cancer Research Consortium (MCCRC).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid</title>
          <description>4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54">6 participants with cancellation, protocol violation and ineligible were excluded from all analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still on treatment</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid</title>
          <description>4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="10.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior tamoxifen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of tamoxifen use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since tamoxifen ended</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior chemotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous fracture by history or X-ray</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone Mineral Density Measurement in Lumbar Spine</title>
          <description>Baseline bone mineral density measurement in lumbar spine for the 30 participants analyzed in primary analysis.</description>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.86" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD)</title>
        <description>Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>The primary analysis is performed on data where participants had the same baseline and 1 year BMD Lumbar Spine measurement location (L1-L4, L2-L4 or ‘other Lumbar Spine’)</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD)</title>
          <description>Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.</description>
          <population>The primary analysis is performed on data where participants had the same baseline and 1 year BMD Lumbar Spine measurement location (L1-L4, L2-L4 or ‘other Lumbar Spine’)</population>
          <units>Percentage of the baseline value</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="1.27" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A sample of 60 participants was estimated to provide percentage statistics accuracy to within 13% with 95% confidence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Lumbar Spine BMD as Measured by DXA at Baseline and at 24, 36, 48, and 60 &gt; Months</title>
        <time_frame>5 yr</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck BMD as Measured by DXA at Baseline and at 12, 24, 36, 48, and 60 Months</title>
        <time_frame>5 yr</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Toxicity as Assessed by NCI CTCAE v3.0</title>
        <time_frame>5 yr</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <time_frame>5 yr</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected within the first year of the study.</time_frame>
      <desc>One participant was excluded from adverse event reporting due to the adverse event data was not available beyond the baseline time point.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid</title>
          <description>4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fever-No ANC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="31" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie L. Hines, M.D.</name_or_title>
      <organization>Mayo Clinic Jacksonville</organization>
      <phone>507-266-0800</phone>
      <email>hines.stephanie@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

